We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$2.7B
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+25.03%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.13B
AUM Growth
-$243M
(-7.2%)
Cap. Flow
-$918M
Cap. Flow
% of AUM
-29.36%
Top 10 Holdings %
Top 10 Hldgs %
37.92%
Holding
89
New
20
Increased
16
Reduced
29
Closed
16
Avg Time Held
4.1
quarters
Top 10 Avg Time Held
2.9
quarters
Top 20 Avg Time Held
2.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$55.4M |
| 2 |
Kodiak Sciences
KOD
|
+$42.4M |
| 3 |
BrightSpring Health Services
BTSG
|
+$40.1M |
| 4 |
Celldex Therapeutics
CLDX
|
+$33.4M |
| 5 |
Illumina
ILMN
|
+$31.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xenon Pharmaceuticals
XENE
|
+$74.8M |
| 2 |
Krystal Biotech
KRYS
|
+$67M |
| 3 |
CG Oncology
CGON
|
+$58.5M |
| 4 |
Apogee Therapeutics
APGE
|
+$54.4M |
| 5 |
Danaher
DHR
|
+$42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.49% |
| 2 | Miscellaneous | 16.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Caris Life Sciences
CAI
$8.66B
| $211M | 6.74% |
7,816,142
+500,000
| +7% | +$14.1M |
2025 Q2
2 quarters
|
|
2
Edgewise Therapeutics
EWTX
$4.03B
| $129M | 4.14% |
5,210,831
| – | – |
2024 Q3
5 quarters
|
|
3
Neurocrine Biosciences
NBIX
$13.7B
| $107M | 3.41% |
751,534
-128,748
| -15% | -$18.7M |
2023 Q1
11 quarters
|
|
4
Glaukos
GKOS
$9.82B
| $104M | 3.33% |
921,979
+141,815
| +18% | +$13.5M |
2022 Q4
12 quarters
|
|
5
DELISTED
Nuvalent
NUVL
| $82.6M | 2.64% |
821,406
-191,576
| -19% | -$18.9M |
2024 Q4
4 quarters
|
|
|
6
Xenon Pharmaceuticals
XENE
$3.25B
| $81.8M | 2.62% |
1,825,076
-1,779,953
| -49% | -$74.8M |
2022 Q4
12 quarters
|
|
|
7
CG Oncology
CGON
$5.46B
| $77.7M | 2.48% |
1,870,571
-1,412,746
| -43% | -$58.5M |
2024 Q1
7 quarters
|
|
8
Hinge Health
HNGE
$8.24B
| $60.6M | 1.94% |
1,304,623
+394,147
| +43% | +$19M |
2025 Q3
1 quarter
|
|
9
Align Technology
ALGN
$10.1B
| $59.5M | 1.9% |
381,004
-28,687
| -7% | -$4.11M |
2022 Q4
12 quarters
|
|
|
10
Kodiak Sciences
KOD
$5.26B
| $58M | 1.85% |
+2,072,788
| New | +$42.4M |
2025 Q4
0 quarters
|
|
11
DELISTED
Soleno Therapeutics
SLNO
| $55M | 1.76% |
1,187,859
-94,130
| -7% | -$5.16M |
2025 Q3
1 quarter
|
|
|
CNTA
12
DELISTED
Centessa Pharmaceuticals
CNTA
| $54.7M | 1.75% |
+2,188,320
| New | +$55.4M |
2025 Q4
0 quarters
|
|
13
NeoGenomics
NEO
$2.18B
| $54.5M | 1.74% |
4,632,801
+2,861,655
| +162% | +$30.9M |
2025 Q3
1 quarter
|
|
14
Acadia Pharmaceuticals
ACAD
$3.27B
| $54.3M | 1.74% |
2,032,021
-346,634
| -15% | -$8.28M |
2025 Q3
1 quarter
|
|
15
Spyre Therapeutics
SYRE
$7.33B
| $53.5M | 1.71% |
1,634,615
-943,789
| -37% | -$24.7M |
2023 Q4
8 quarters
|
|
16
Dianthus Therapeutics
DNTH
$4.22B
| $52.5M | 1.68% |
1,273,935
+438,878
| +53% | +$17M |
2025 Q3
1 quarter
|
|
|
17
Celldex Therapeutics
CLDX
$2.19B
| $50.5M | 1.61% |
1,858,109
+1,266,420
| +214% | +$33.4M |
2025 Q3
1 quarter
|
|
18
Inspire Medical Systems
INSP
$1.97B
| $49.9M | 1.6% |
540,890
-342,857
| -39% | -$32.8M |
2023 Q3
9 quarters
|
|
|
19
Krystal Biotech
KRYS
$9.56B
| $49.8M | 1.59% |
202,101
-318,300
| -61% | -$67M |
2022 Q4
12 quarters
|
|
20
Intuitive Surgical
ISRG
$147B
| $47.2M | 1.51% |
83,417
-46,810
| -36% | -$24.9M |
2024 Q1
7 quarters
|
|
21
Thermo Fisher Scientific
TMO
$249B
| $46.8M | 1.5% |
80,725
-33,208
| -29% | -$18.8M |
2024 Q4
4 quarters
|
|
|
22
BrightSpring Health Services
BTSG
$12.5B
| $44.8M | 1.43% |
+1,195,786
| New | +$40.1M |
2025 Q4
0 quarters
|
|
23
CVS Health
CVS
$115B
| $44.8M | 1.43% |
564,200
+125,600
| +29% | +$9.9M |
2025 Q3
1 quarter
|
|
|
24
DELISTED
Apogee Therapeutics
APGE
| $43.4M | 1.39% |
575,067
-863,678
| -60% | -$54.4M |
2023 Q3
9 quarters
|
|
25
Nurix Therapeutics
NRIX
$2.59B
| $41.4M | 1.32% |
+2,183,864
| New | +$31.4M |
2025 Q4
0 quarters
|
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q4 2025 Portfolio in Review
As of Q4 2025, Braidwell held 89 positions worth $3.13B, down 7.2% from $3.37B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Braidwell withdrew a net $918M in Q4 2025, closing 16 positions and reducing 29 holdings. Its most notable exit was Globus Medical, an estimated $28.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 73% a quarter earlier, followed by Miscellaneous.
Against the trend, Braidwell opened a new position in Centessa Pharmaceuticals worth $54.7M.
- Braidwell's largest Q4 2025 buy was Centessa Pharmaceuticals: 2,188,320 shares worth $54.7M.
- Braidwell added most to Celldex Therapeutics in Q4 2025, an estimated $33.4M increase.
- Braidwell's biggest Q4 2025 reduction was Xenon Pharmaceuticals, cutting an estimated $74.8M.
- Braidwell fully exited Globus Medical in Q4 2025, selling an estimated $28.5M.
- Braidwell's ten largest holdings make up 38% of its $3.13B portfolio in Q4 2025.
- Braidwell opened 20 new positions and closed 16 in Q4 2025.
- Braidwell's portfolio value fell 7.2% quarter-over-quarter to $3.13B.
Based on Braidwell's 13F filing for Q4 2025, filed 17 Feb 2026.